Loading...
•
Apr 30, 2022
KalVista Q4 2022 Earnings Report
KalVista reported financial results for the fourth quarter and fiscal year ended April 30, 2022.
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the three months ended April 30, 2022. Research and development expenses were $19.2 million, and general and administrative expenses were $7.6 million. The net loss for the quarter was $24.1 million, or $(0.98) per share. Cash, cash equivalents, and marketable securities totaled $166.2 million as of April 30, 2022.
Enrollment is proceeding as expected for the Phase 3 KONFIDENT trial for sebetralstat, with data expected in the second half of 2023.
The Phase 2 KOMPLETE clinical trial for KVD824 also remains on track with its enrollment targets, and data from the KOMPLETE trial is expected in mid-2023.
KalVista reported promising preclinical data for its oral factor XIIa inhibitor program at the KININ2022 conference.
The Company is well-capitalized, with funding until at least early 2024, which is expected to take them beyond data from both ongoing clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...